Blog

  • Iran says enriched uranium stockpile buried under bombed sites

    Iran says enriched uranium stockpile buried under bombed sites

    Unlock the Editor’s Digest for free

    Iran has said its stockpile of enriched uranium remains beneath the rubble of the nuclear sites bombed by Israel and the US, a rare public reference to the whereabouts of its fissile material.

    The status of the stockpile — particularly 408kg of uranium enriched close to weapons-grade levels — has been a key concern of western powers in the wake of Israel’s 12-day war against the Islamic republic in June.

    Iranian foreign minister Abbas Araghchi told state television on Thursday night that the nuclear materials were all “located under the debris of the bombed installations”.

    He added that Iran’s Atomic Energy Organization was “assessing whether these materials are accessible or not”.

    Araghchi’s comments come as Iran faces a looming deadline to meet conditions set by European powers, including addressing concerns about the stockpile of highly enriched uranium, or having international sanctions reimposed on the Islamic republic at the end of the month.

    Since Israel’s war, western intelligence assessments on the extent of damage to Iran’s programme have been mixed.

    Iranian foreign minister Abbas Araghchi said the nuclear materials were all ‘located under the debris of the bombed installations’ © Khaled Elfiqi/AP

    President Donald Trump said the programme had been “obliterated” after the US briefly joined Israel’s attack, bombing Iran’s main enrichment facilities, Fordow and Natanz, as well as another nuclear site and storage facility in Isfahan.

    But diplomats and nuclear experts suspect that Tehran may have moved the stockpile of highly enriched uranium before the strikes.

    After the war, Iran suspended co-operation with the International Atomic Energy Agency, meaning the UN nuclear watchdog has neither been able to assess the full scale of the damage nor what happened to the stockpile.

    The UK, Germany and France cited Tehran’s failure to allow the IAEA to resume full inspections and clarify the status of the enriched uranium as reasons behind their decision to activate a so-called snapback process on August 28, which will lead to the reimposition of UN sanctions on Iran.

    They have also said Tehran must resume nuclear talks with the Trump administration.

    Under the snapback mechanism — which is part of a 2015 deal Tehran signed with the so-called E3, the Obama administration, Russia and China — there is a 30-day period before the sanctions come back into effect. That provides a narrow window for diplomacy and the potential for the process to be extended, if Iran meets the E3’s conditions.

    Ellie Geranmayeh, at the European Council on Foreign Relations, said the E3’s response to Araghchi’s comments was likely to be: “Prove it.”

    But she added that the European conditions to Iran were “detached from the realities following the June strikes”.

    “For Tehran, providing the west with eyes and ears on the ground, and clarity over its highly enriched stockpile, is one of the few bargaining cards it has left,” Geranmayeh said. “Iran is trying to preserve ambiguity over its nuclear programme — both to keep its options open over weaponisation, but more likely to draw Trump back into talks.”

    Iran began expanding its nuclear activity after Trump withdrew from the nuclear accord in 2018 and imposed waves of sanctions on the Islamic republic. The European powers are still signatories to the 2015 accord.

    Tehran was in the midst of nuclear talks with the Trump administration when Israel launched its attack in June.

    Rafael Grossi, IAEA director-general, said this week that the agency and Tehran had reached a preliminary agreement to resume co-operation, describing it as “an important step”.

    But there were scant details of the agreement, including when IAEA inspectors would be able to visit Fordow and Natanz.

    Araghchi said on Thursday that “no inspection is currently on the agenda”. He reiterated that the agreement with the IAEA would be void if the E3 implemented snapback.

    The E3 have said they remain committed to diplomacy, but they are wary about whether Iran will allow full IAEA inspections.

    “Iran is obfuscating the status and location of this material from the international community, and Iran refused to allow the agency to verify this stockpile,” they said in a joint statement to the agency’s board this week.

    Continue Reading

  • After a Big Drop Yesterday, Gold Price Rises Rapidly Again

    After a Big Drop Yesterday, Gold Price Rises Rapidly Again

    Gold prices in Pakistan rose on Friday, following an uptrend in the international market.

    Data from the All-Pakistan Gems and Jewellers Sarafa Association showed the local price per tola increased by Rs. 2,500 to Rs. 386,500, while the 10-gram rate climbed Rs. 2,143 to Rs. 331,361.

    The association reported that international gold prices also advanced, reaching $3,645 per ounce with a $20 premium, up $27 from the prior session.

    Silver prices in the local market gained Rs. 130, taking the per tola rate to Rs. 4,456.

    On Thursday, domestic gold prices had dropped by Rs. 4,100 per tola to Rs. 384,000.

    Globally, spot gold rose 0.5% to $3,651.92 per ounce.


    Continue Reading

  • Gold creeping closer to $3,700

    Gold creeping closer to $3,700

    Gold (GC=F) futures opened at $3,672.80 per ounce on Friday, up 1% from Thursday’s close of $3,636.90. Gold has been trading in a narrow range since Wednesday, yet reached as high as $3,695.50 this morning.

    Gold prices did not respond meaningfully to a higher-than-expected Consumer Price Index report for August. Prices rose 0.4% after rising 0.2% in July. Groceries and gas were up 0.5% and 1.9%, respectively. Despite the inflation uptick, investors still expect the Fed to lower interest rates next week in response to a weakening employment situation in the U.S. Lower interest rates could fuel even higher prices.

    Learn more: Gold Rises Toward Record as ETFs Expand in Run-Up to Fed Meeting

    Gold tends to benefit from lower interest rates and higher prices, for different reasons. Lower interest rates make the precious metal look more attractive relative to cash and fixed income. And gold’s status as a safe-haven asset prompts higher demand when prices rise.

    The opening price of gold futures on Friday is up 1% from Thursday’s close of $3,636.90 per ounce. Friday’s opening price is up 2.9% from the opening price of $3,567.80 one week ago on September 5. In the past month, the gold futures price has increased 9.4% compared to the opening price of $3,356.20 on August 12, 2025. In the past year, gold is up 45.2% from the opening price of $2,529.10 on September 12, 2024.

    24/7 gold price tracking: Don’t forget you can monitor the current price of gold on Yahoo Finance 24 hours a day, seven days a week.

    Want to learn more about the current top-performing companies in the gold industry? Explore a list of the top-performing companies in the gold industry using the Yahoo Finance Screener. You can create your own screeners with over 150 different screening criteria.

    The next time you shop Costco (COST), you may want to pick up some gold with that rotisserie chicken. Gold prices have been on a run lately, and what more convenient place can you find to buy a commodity?

    In fact, the club store sells gold bars, silver coins, and platinum bars — three precious metals that many investors use to diversify their wealth.

    The club store first offered gold bars in 2023, then added silver (SI=F) and platinum over the next year or so. Meanwhile, gold is hanging around its all-time high. Gold, silver, and platinum are all up substantially so far in 2025.

    Intrigued by Costco’s precious metals offering? Read more here to learn key considerations for precious metals investing, the details of the Costco selection, and tips for managing your new investment.

    Whether you’re tracking the price of gold since last month or last year, the price-of-gold chart below shows the precious metal’s steady upward climb in value.

    Historically, gold has shown extended up cycles and down cycles. The precious metal was in a growth phase from 2009 to 2011. It then trended down, failing to set a new high for nine years.

    In those lackluster years for gold, your position will negatively impact your overall investment returns. If that feels problematic, a lower allocation percentage is more appropriate. On the other hand, you may be willing to accept gold’s underperforming years so you can benefit more in the good years. In this case, you can target a higher percentage.

    The precious metal has been in the news lately, and many analysts are bullish on gold. In May, Goldman Sachs Research predicted gold would reach $3,700 a troy ounce by year-end 2025. That would equate to a 40% increase for the year, based on gold’s January 2 opening price of $2,633. Rising demand from central banks, along with uncertainty related to changing U.S. tariff policy, are the factors driving the increase.

    If you are interested in learning more about gold’s historical value, Yahoo Finance has been tracking the historical price of gold since 2000.

    Continue Reading

  • Shehbaz Sharif lays foundation stone for T-Chowk Flyover – RADIO PAKISTAN

    1. Shehbaz Sharif lays foundation stone for T-Chowk Flyover  RADIO PAKISTAN
    2. Pakistan to host next SCO summit: PM Shehbaz  Dawn
    3. PM performs groundbreaking of T-Chowk Flyover Project  Associated Press of Pakistan
    4. PM Sharif sets 2027 SCO summit as target for Islamabad’s transformation  Profit by Pakistan Today
    5. PM inaugurates stone laying ceremony of T-Chowk Flyover in capital  Abb Takk News

    Continue Reading

  • Podcast: key trials and trends from ESC Congress 2025

    Podcast: key trials and trends from ESC Congress 2025

    The editorial team covers all the latest drug and medical device news from this year’s ESC Congress. JuShoot via Shutterstock.com.

    Eyes in the pharma and medtech industries are directed to the European Society of Cardiology (ESC) Congress every year to examine the latest clinical trial data, observational study results, and real-word evidence in the cardiology space.

    On this episode, the healthcare editorial team unpicks several key trials and trends from this year’s event, held from 29 August to 1 September in Madrid.

    Discover B2B Marketing That Performs

    Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

    Find out more

    Data at ESC is from studies evaluating investigational drug or medical device candidates, but also from trials analysing approved therapies.

    Pharmaceutical Technology editor Robert Barrie sat down with Abigail Beaney, editor of Clinical Trials Arena, and Ross Law, reporter for Medical Device Network, who both covered the congress, to discuss data presented.



    Continue Reading

  • Progress in clinical development for Alzheimer’s and other

    Progress in clinical development for Alzheimer’s and other

    • GAL-101 was well tolerated; excellent safety and pharmacokinetic profile strongly support oral administration
    • GAL-101 effectively crosses the blood-brain barrier, supporting further development in Alzheimer’s disease
    • A Phase 2 trial in Alzheimer’s disease is planned as the next step, fundraising has been initiated

    KENSINGTON, Md. and MUNICH and MARTINSRIED, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) — Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and retinal diseases, today announced the completion of its Phase 1 study with orally administered GAL-101, a small molecule specifically designed to target misfolded amyloid beta (Aβ) monomers. In the trial, GAL-101 was shown to be well tolerated and clinically safe, with no serious adverse events (SAEs) observed. Consistent with pre-clinical findings, GAL-101 was shown to effectively cross the blood-brain barrier, and its pharmacokinetic (PK) profile strongly supports advancing the oral formulation in Phase 2 development in Alzheimer’s disease. The full study results are expected to be presented at a future scientific conference.

    “Completing our first clinical trial with the oral formulation of GAL-101 is an important milestone for Galimedix,” said Alexander Gebauer, MD, PhD, Co-founder and Executive Chairman of Galimedix. “We are pleased that the results showed that oral GAL-101 was well tolerated with a highly favorable safety profile. Additionally, the pharmacokinetic profile strongly supports the planned administration route, as well as continued development for the treatment of Alzheimer’s disease. We are planning a Phase 2 trial in Alzheimer’s disease, an indication for which patients today have very limited treatment options. GAL-101 is expected to be first-in-class and has the potential to become the future standard of care for all stages of Alzheimer’s, including mild cognitive impairment.”

    The Phase 1 trial enrolled a total of over 100 healthy volunteers and evaluated the safety, tolerability and pharmacokinetics of single (SAD) and multiple (MAD) ascending oral doses of GAL-101. The study also evaluated GAL-101’s ability to cross the blood-brain barrier, as well as a variety of other parameters, including the effects of food, age and gender, all of the relevant aspects required to initiate Galimedix’s planned Phase 2 study in Alzheimer’s disease.

    Galimedix is also conducting a Phase 2 clinical trial with GAL-101 eyedrops for dry age-related macular degeneration (dAMD); recruitment in the eDREAM study is ongoing in the US, Europe, and other regions. The development in dAMD/geographic atrophy (GA) is partner funded, mitigating the financial exposure of Galimedix.

    Galimedix is prepared to discuss the available data and investment and partnering opportunities with interested parties.

    Connect with Galimedix
    To learn more, investors and partners are invited to connect with Galimedix management, who will attend the following fall conferences:

    • LSX World Congress USA, Boston, MA, September 15-17
    • 25th Annual Biotech in Europe Forum, Basel, Switzerland, October 8-9
    • BIO-Europe, Vienna, Austria, November 3-5
    • LSX Inv€$tival, London, UK, November 17

    To schedule a meeting or call, please reach out to info@galimedix.com.

    About GAL-101
    GAL-101 is a small molecule targeting misfolded Aβ monomers and thus preventing the formation of toxic Aβ oligomers and protofibrils. It is being developed in both oral and topical (eyedrops) formulations. Many studies have indicated that these Aβ aggregates are a major underlying cause of neurodegenerative diseases of the brain and retina, and recent approvals of anti-Aβ drugs have also validated them as a key target in Alzheimer’s disease. GAL-101 is being developed for the treatment of dAMD, glaucoma and Alzheimer’s disease.

    In pre-clinical testing, the compound has been shown to prevent and eliminate all forms of toxic Aβ species while leaving healthy Aβ forms intact. GAL-101 has also demonstrated the potential for neuroprotection and for symptomatic alleviation in pre-clinical models of Alzheimer’s disease. Additionally, orally available GAL-101 has shown no antibody-specific immunological side effects (e.g., ARIA), very low systemic toxicity, robust storage stability, and easy and inexpensive manufacturing. Strong efficacy has also been demonstrated in relevant ophthalmic pre-clinical models, protecting neuronal retinal cells from toxic damage. In a previous Phase 1 study, GAL-101 eyedrops demonstrated an excellent safety and tolerability profile. The eDREAM Phase 2 study (NCT06659549) in dAMD/GA with GAL-101 eyedrops is ongoing.

    About Galimedix Therapeutics, Inc. 
    Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and retinal diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in Alzheimer’s disease, dry age-related macular degeneration (dAMD) and glaucoma – Galimedix’s initial areas of focus.

    Contact 
    Alexander Gebauer, MD, PhD 
    Galimedix Therapeutics, Inc.
    Co-founder and Executive Chairman
    info@galimedix.com

    Media inquiries: 

    Anne Hennecke U.S.
    MC Services AG Laurie Doyle
    Tel: +49 (0)170 7134018 Tel: +1-339-832-0752
    galimedix@mc-services.eu  

    Continue Reading

  • A New Neutrino Detector In China Is Coming Online

    A New Neutrino Detector In China Is Coming Online

    Neutrinos are one of the most enigmatic particles in the standard model. The main reason is that they’re so hard to detect. Despite the fact that 400 trillion of them created in the Sun are passing through a person’s body every second, they rarely interact with normal matter, making understanding anything about them difficult. To help solve their mysteries, a new neutrino detector in China recently started collecting data, and hopes to provide insight on between forty and sixty neutrinos a day for the next ten years.

    The detector, known as the Jiangmen Underground Neutrino Observatory, or JUNO, is located in between two huge nuclear plants at Yangjian and Taishan. Both of those fission plants create their own artificial neutrinos in addition to the ones created by the Sun, meaning the general area should be awash with barely interacting particles.

    That’s despite the fact that, like most neutrino detectors, it’s located underground. 700 meters underground in fact. The physical bulk of the Earth’s crust is meant to block most other particles, like muons, from getting to it, and at other installations, like IceCube, it does a pretty good job.

    The inside of the sphere with the scintillating liquid. Credit – JUNO Collaboration

    Even so, the detector itself is covered by an additional detector called the “Top Tracker”, which is covering a 44m diameter pool of ultrapure water. Its job is to detect any stray particle that might make it all the way down to the detector. Ultimately it can’t stop them, but it can eliminate the data artifact they might create.

    That data artifact would happen if one of the particles hits the “liquid scintillator” inside a sphere surrounded by 43,212 sensitive photodetectors that can pick up individual photons.Combining data from all of the different photodetectors would allow researchers to tease out some of the physical properties of neutrinos, including what, if any, differences there are between the three “types”.

    Those are the electron, the muon, and the tau neutrino. Each has slightly different characteristics from one another, and they have the ability to shift between the different types, or “oscillate” in the language of particle physicists. One of the main goals of JUNO is to understand the mass of each, but, given that ask is probably too much, researchers are at least hoping to get a sense of the hierarchy of masses – i.e. which one is heaviest vs lightest. Another potential discovery is how often the types change from one to another – i.e. what is the frequency of their oscillation.

    The Top Tracker covering the pool of water surrounding the detector. Credit - JUNO Collaboration The Top Tracker covering the pool of water surrounding the detector. Credit – JUNO Collaboration

    Understanding how neutrinos work would unlock a clearer picture of cosmology, where they are thought to be responsible for the early expansion during the big bang, astrophysics, since they are thought to provide insights into supernovae, and even geology, as radioactive rocks from deep within the Earth emit them. That’s part of the reason scientists have invested so much time and energy into tracking down their properties.

    JUNO is the next step in that journey. The setup itself is a collaboration of 74 institutes and 700 individuals, and is led by the Chinese Academy of Science’s Institute for High Energy Physics. It should operate for at least ten years and hopes to collect enough data over that time frame to shed some additional light on the characteristics of these enigmatic particles. If it does, then multiple realms of science will be better for it.

    Learn More:

    CNRS – JUNO: a giant detector to unravel the mysteries of neutrinos

    UT – An Unfinished Detector has Already Spotted the Highest-Energy Neutrino Ever Seen

    UT – Catching Ghost Particles in Real Time

    UT – IceCube Just Spent 10 Years Searching for Dark Matter

    Continue Reading

  • Armani’s will instructs heirs to sell fashion brand or seek listing

    Armani’s will instructs heirs to sell fashion brand or seek listing

    Designer Giorgio Armani appears at the end of his Haute Couture Fall/Winter 2024-2025 collection show for Giorgio Armani Prive in Paris, France, June 25, 2024. 

    Yves Herman | Reuters

    Late designer Giorgio Armani has instructed heirs to gradually sell the fashion brand he created 50 years ago or seek a stock market listing, his will said, marking a surprising turn for a company highly protective of its independence and Italian roots.

    The will, reviewed by Reuters, states heirs should sell an initial 15% stake in the Italian fashion house within 18 months and later transfer an additional 30% to 54.9% stake to the same buyer between three and five years after Armani’s death. The designer, known in the industry as “King Giorgio,” died on Sept. 4 at 91 and with no children.

    The will also says that priority should be given to luxury giant LVMH, beauty heavyweight L’Oreal, eyewear leader EssilorLuxottica or another group of “equal standing” identified by a foundation the designer set up to preserve his legacy with the agreement of Armani’s business and life partner, Pantaleo Dell’Orco.

    Alternatively, an initial public offering should be pursued, in Italy or in a market of equal standing, it said.

    The explicit mention of stake sales and of France-listed players as potential buyers is in stark contrast with Giorgio Armani’s persistent refusal to dilute his control or list his fashion group on the stock market.

    Over the years, the maker of popular unstructured suits that gained him international fame received several approaches, including one in 2021 from John Elkann, scion of Italy’s Agnelli family, and another from luxury brand Gucci, when Maurizio Gucci was still at the helm.

    Armani was the sole major shareholder of the company he set up with his late partner Sergio Galeotti in the 1970s and over which he maintained a tight rein — both creative and managerial — until the very end.

    He has left behind no children to inherit the business, which generated relatively stable revenue — 2.3 billion euros ($2.7 billion) in 2024 — but whose profits have shrunk amid a broad luxury industry recession.

    The will gives the Fondazione Giorgio Armani and life partner and right-hand man Pantaleo Dell’Orco 70% of voting rights in the Armani group combined.

    The foundation will retain a 30.1% stake in the event of a listing, according to the will.

    Heirs should consider other fashion and luxury companies with which Armani’s company has commercial ties for a future sale, the will also said.

    Continue Reading

  • Actor Jeff Bridges Reflects on Recovery, Family, and Hope in Blood Cancers & Disorders Campaign

    NEW YORK, Sept. 12, 2025 /PRNewswire/ — Blood cancers and disorders affect millions of people across the globe, presenting not only medical challenges but also emotional and financial ones. From leukemia and lymphoma to sickle cell disease and bone marrow disorders, these conditions impact patients and families at every stage of life. To raise awareness during Blood Cancer Awareness Month and beyond, amplify patient voices, and share the latest in diagnostics, therapies, and care, Mediaplanet is proud to launch the ‘Blood Cancers & Disorders’ campaign.






    Blood Cancers and Disorders




    Blood Cancers and Disorders

    Actor Jeff Bridges shares his story as the campaign’s cover feature, offering a deeply personal perspective as a lymphoma survivor. Reflecting on his treatment and recovery, Bridges shares how gratitude, teamwork, and love carried him through. “I’m very fortunate and grateful, and it’s brought both of those things to the forefront of my life. I find that love is very present,” he said. From hospital days spent waving to his family through windows during COVID, to setting small “sporting event” goals with his medical team and physical therapist, Bridges’ story illustrates the resilience and humanity behind every cancer journey. 

    The campaign also features insights from leading hematologist-oncologists, patient advocates, and public health experts, offering both practical guidance and hope to those newly diagnosed as well as those navigating long-term survivorship. By spotlighting advances in early detection, innovative treatments, and supportive care resources, the campaign aims to empower patients and their loved ones with the knowledge they need to move forward.

    The print component of “Blood Cancers & Disorders” is distributed in today’s edition of USA Today. The digital component is distributed nationally, through a vast social media strategy, and across a network of top news sites and partner outlets. To explore the digital version of the campaign, visit: https://www.futureofpersonalhealth.com/campaign/blood-health/.

    This campaign was made possible with the support of Jeff Bridges, American Society of Hematology, Aplastic Anemia & MDS International Foundation (AAMDSIF), Blood Cancer United (LLS), MPN Research Foundation, Lymphoma Research Foundation, American Society of Pediatric Hematology/Oncology (ASPHO), Red Sox Pitcher Liam Hendriks and features paid content from Alexion/AstraZeneca, Sobi/VONJO and Children’s Hospital Colorado.

    Company Contact

    Shannon Ruggiero

    [email protected]

    SOURCE Mediaplanet

    Continue Reading

  • AI robo-nurse to takeover healthcare sector

    AI robo-nurse to takeover healthcare sector



    AI robo-nurse to takeover healthcare sector

    Taiwan based tech company, Foxconn has developed an artificial intelligence powered nursing robot, Nurabot, which is designed to sort out critical staffing shortages issues in healthcare systems worldwide.

    The Chinese language model enables communication with patients and staff while adapting behavior based on specific situations and contexts.

    Autonomous assistants can handle repetitive tasks like medication delivery and patient guidance, currently reducing nursing workload by 20-30% in trials at Taiwan’s Taichung Veterans General Hospital.

    The humanoid robot, developed in just 10 months through collaboration with Kawasaki Heavy Industries and NVIDIA, uses advanced sensors and AI navigation to move independently through hospital wards.

    World Health Organization (WHO) data revealed: “Healthcare faces a projected global shortage of 4.5 million nurses by 2030, compounded by aging populations and high burnout rates among existing staff.”

    AI robo-nurse to takeover healthcare sector

    Foxconn design director Alice Lin expressed that the hospital bounded automated machine plans to free nurses for complex decision making tasks rather than replacing human workers entirely.

    In addition to that, the system undergoes rigorous safety testing before planned commercial launch in early 2026, with Foxconn currently declining to disclose anticipated pricing.

    Major development represents growing investment in smart hospital technology, a sector projected to reach $72 billion this year.

    Texas-developed Moxi robots, a similar version to Nurabot, already operate in U.S. hospitals, though experts believe continued need for evidence regarding actual workload reduction versus perceived benefits.

    Continue Reading